Dr. Judah Folkman is considered the "father of angiogenesis." Because of Folkman's discovery and research, the possibilities of angiogenic therapy have broadened beyond cancer to many noncancerous diseases. Angiogenesis: An Integrative Approach from Science to Medicine is a comprehensive, concise summary of tumor angiogenesis. It is an up-to-date and authoritative reference for the angiogenesis field as it relates to oncology. This book represents the first collection in a volume of which Folkman is co-editor. Folkman has authored nearly 400 original papers and more than 100 book chapters.
In 1961, twenty-eight-year-old Dr. Judah Folkman saw something while doing medical research in a United States navy lab that gave him the first glimmering of a wild, inspired hunch. What if cancerous tumors, in order to expand, needed to trigger the growth of new blood vessels to feed themselves? And if that was true, what if a way could be found to stop that growth? Could cancers be starved to death? Dr. Folkman had ample reason to be self confident — second in his class at Harvard Medical School, he was already considered one of the most promising doctors of his generation. But even he never guessed that his idea would eventually grow into a multibillion-dollar industry that is now racing through human trials with drugs that show unparalleled promise of being able to control cancer, as well as other deadly diseases. For the creation of this book, Dr. Judah Folkman cooperated fully and exclusively with acclaimed science writer Robert Cooke. He granted Cooke unlimited interviews, showed him diaries and personal papers, and threw open the doors of his lab. The result is an astonishingly rich and candid chronicle of one of the most significant medical discoveries of our time and of the man whose vision and persistence almost single-handedly has made it possible. Dr. Folkman's radical new way of thinking about cancer was once considered preposterous. So little was known about how cancer spreads and how blood vessels grow that he wasn't even taken seriously enough to be considered a heretic. Other doctors shook their heads at the waste of a great mind, and ambitious young medical researchers were told that accepting a position in Folkman's lab would be the death of their careers. Now, though, the overwhelming majority of experts believes that the day will soon come when antiangiogenesis therapy supplants the current more toxic and less-effective treatments — chemotherapy, radiation, and surgery-as the preferred method of treatment for cancer in patients around the world, and Dr. Folkman's breakthrough will come to be taken for granted the way we now take for granted the polio vaccine and antibiotics. Dr. Folkman's War brilliantly describes how high the odds are against success in medical research, how vicious the competition for grants, how entrenched the skepticism about any genuinely original thinking, how polluted by politics and commerce the process of getting medicine into patients' hands. But it also depicts with rare power how exalted a calling medicine can be and how for the rare few—the brilliant, the tireless, and the lucky — the results of success can be world-changing. From the Hardcover edition.
The aim if this book is to analyze the scientific biography of Judah Folkman, one of the most important scientist of the last century. More 50 years ago, Folkman found a revolutionary new way to think about cancer. Blood supply, Folkman hypothesized, was the key to tumor growth. Without new blood vessels, tumors simply did not thrive. In 1971, Folkman published his theory of angiogenesis in the “New England Journal of Medicine”. Angiogenesis, the formation and recruitment of new blood vessels, is necessary for tumor growth. Critics of the theory were silenced over time as Folkman and his colleagues reported the first purified angiogenic molecule, the first angiogenesis inhibitor and proposed the concept of angiogenic disease. The mechanism of angiogenesis is now a worldwide field of investigation. Over the years, Folkman and a growing team of researchers have isolated the proteins and unraveled the processes that regulate angiogenesis. Meanwhile, a new generation of angiogenesis research has emerged as well, widening the field into new areas of human disease and deepening it to examine the underlying biological processes responsible for those diseases.
Drs. Groopman and Hartzband reveal a clear path for making the right medical choices. Such factors as authority figures, statistics, other patients' stories, technology, and natural healing are key factors that shape choices.
Angiogenesis, the formation of new blood vessels, is fundamental for physiological processes such as embryonic and postnatal development, wound repair, and reproductive functions. Angiogenesis plays a major role in tumor growth and in several autoimmune and allergic disorders. Lymphangiogenesis, the formation of new lymphatic vessels, is also important for tumor growth, the formation of metastasis, and chronic inflammatory diseases. Judah Folkman, a pioneer in the study of angiogenesis, first proposed that macrophages and mast cells could be a relevant source of angiogenic factors. Since then, much effort has gone into the elucidation of the role of immune cells in the modulation of angiogenesis and lymphangiogenesis. There is now compelling evidence that several components of the innate and adaptive immune system are implicated in inflammatory and neoplastic angiogenesis and lymphangiogenesis. Articles in this volume deal with the emerging, intriguing possibility that immune cells are both a source and a target of angiogenic and lymphangiogenic factors. Therefore, cells of the immune system might play a role in inflammatory and neoplastic angiogenesis/lymphangiogenesis through the expression of several angiogenic factors and their receptors and co-receptors. The important new findings in this volume will be of special interest to vascular biologists, basic and clinical immunologists, oncologists and to specialists in allergic and immune disorders.
Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. This book is written by internationally renowned experts. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.
The author helps readers figure out which leaders matter, why, and when - and what lessons they can learn from those who do matter. Leaders from politics and business are profiled, they include: Abraham Lincoln, Neville Chamberlain, Woodrow Wilson, Thomas Jefferson, Winston Churchill, Jamie Dimon, Al Dunlap, Sir Jacky Fisher, and Judah Folkman.
The participation of endothelial cells in various physiologic and pathologic processes has been hypothesized since before the turn of the century. However, until recently, direct evidence for endothelial involvement in these processes has been extremely difficult to obtain due to the inability to study endothelial cell function in vitro. Though the possibility of using cultured endothelial cells to study endothelial cell function in vitro was recognized many years ago, the inability to culture unambiguously identifiable endothelial cells limited investigators in their studies of endothelial function. As a result, the field of endothelial cell biology lay relatively fallow for many years. The development in the early 1970's of routine and easily implemented methods for culturing human endothelial cells and the demonstration that cultured endothelial cells synthesized a physiologically relevant protein, Factor VIII/von Willebrand Factor, quickly changed this state of affairs. Over the following decade the scope of endothelial cell research rapidly widened, spreading in a number of directions. First, methods were developed to culture endothelial cells from a variety of species. Second, methods were developed to culture endothelial cells from different organs and types of blood vessels (arteries, veins, and capillaries) within a single species. Third, and most important, investigators began using cultured endothelial cells as tools to study the potential involvement of endothelial cells in a wide assortment of biologically interesting processes. The net result has been a tremendous increase in our understanding of endothelial cell function.
Is it advisable to go back from bedside to the bench? During the last decade, few topics encountered such a broad interest in bio- gy and medicine as angiogenesis. The amazing ability of the body to restore blood flow by induction of blood vessel growth as part of an adaptive process has alarmed physicians dealing with diseases in which angiogenesis is either exaggerated (as in tumors) or too slow (as in ischemic diseases of heart and brain). Not surprisingly, pro- and antiangiogenic strategies have found their way into clinical trials. For instance, for the USA, the NIH website in early 2004 displayed 38 clinical studies involving either pro- or antiangiogenic th- apies. Given the expected overwhelming wealth of clinical data, the question may be asked whether further exploration of biological mechanisms is required or whether results from the bedside are instructive enough to proceed. This question depends also on the progress of pro- and antiangiogenic clinical trials. In the following, I give a short overview about some of the progress that has been made in this field. Since Judah Folkman proposed antiangiogenic tumor therapy thirty years ago, it has become increasingly evident that agents which interfere with blood vessel formation also block tumor progression. Accordingly, antiangiogenic therapy has gained much attention as a potential adjunct to conventional c- cer therapy.
This collection of anthropology of science essays explores the new forms of capital, markets, ethical, legal, and intellectual property concerns associated with new forms of research in the life sciences.
